Matrix Metalloproteinases and Diabetic Nephropathy
Matrix Metalloproteinases and Diabetic Nephropathy
This study is currently recruiting participants.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), June 2008
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00067886
Purpose
Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs. Abnormal activity of these enzymes has been implicated in many disease processes including rheumatoid arthritis, dental disease and metastatic cancer. Recent studies also suggest that elevations in blood sugar may abnormally effect MMP enzyme activity. Decreased activity of some of these MMP enzymes may be a partial cause of the abnormal enlargement of the kidney (renal hypertrophy) seen at the start of diabetic kidney disease (nephropathy). Preliminary clinical data from our laboratory confirm that children with newly diagnosed type 1 diabetes mellitus (DM) have lower blood levels of some of these enzymes at the time of very high blood sugar readings. However, these enzyme levels become normal again as blood sugar levels improve with insulin treatment. In the present study, we propose to investigate the hypothesis that MMPs are involved in the cause of diabetic kidney disease by measuring concentrations of specific MMPs and some related proteins in the blood and urine of patients with type 1 DM who are between the ages of 14-40 years. We will enroll some patients who are recently diagnosed with diabetes, some who have had diabetes for several years, but without signs of kidney disease, and some with long-term diabetes and various degrees of kidney disease. Continuous Subcutaneous Glucose Monitoring, conducted for 3-4 days, will also be provided as a part of this study, to determine how different levels of blood sugar control might relate to different levels of MMP enzyme activity in the blood. We anticipate that this study will help to establish a link between abnormal MMP activity and the cause of nephropathy in type 1 DM, allowing scientists to design better therapies for the prevention and treatment of diabetes-related kidney problems.
Condition
Diabetes Mellitus, Type 1
Diabetic Nephropathy
MedlinePlus related topics: Diabetes Diabetes Type 1 Diabetic Kidney Problems
U.S. FDA Resources
Study Type:Observational
Study Design:Case Control, Cross-Sectional
Official Title:Matrix Metalloproteinases and Diabetic Nephropathy
Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Biospecimen Retention: None Retained
Biospecimen Description:
Estimated Enrollment:330
Study Start Date:March 2003
Estimated Study Completion Date:December 2008
Eligibility
Ages Eligible for Study:14 Years to 40 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Yes
Sampling Method:Non-Probability Sample
Study Population
Type 1 Diabetes mellitus, ages 14-40 years.
Criteria
Type 1 Diabetes with or without kidney disease and past puberty.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00067886
Locations
United States, Arkansas
Arkansas Children's Hospital/University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Cynthia S Moreau, RN 501-364-1975 moreaucynthias@uams.edu
Contact: Kathy Edwards, RN 501-364-1430
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Kathryn M Thrailkill, MD Arkansas Chilldren's Hospital Research Institute
More Information
Publications of Results:
Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care. 2007 Sep;30(9):2321-6. Epub 2007 Jun 11.
Responsible Party:Arkansas Children's Hospital Research Institute ( Kathryn Thrailkill )
Study ID Numbers:MMADN (DK62999)
First Received:August 29, 2003
Last Updated:June 6, 2008
ClinicalTrials.gov Identifier:NCT00067886 [history]
Health Authority:United States: Federal Government
Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Kidney Diseases
Metabolic disorder
Glucose Metabolism Disorders
Diabetes Complications
Additional relevant MeSH terms:
Immune System Diseases
